• DMH1 Workflows for BMP and Organoid Research

  2026-08-17

  DMH1 is a selective ALK2 inhibitor for dissecting BMP-driven signaling, organoid behavior, and NSCLC phenotypes. This workflow-focused guide connects pathway-specific readouts with practical stock preparation, concentration scouting, migration assays, and organoid optimization while clearly separating established evidence from testable extensions.

• EZ Cap™ Human PTEN mRNA: Translational Cancer Strategy

  2026-08-16

  A mechanistic and translational roadmap for using EZ Cap™ Human PTEN mRNA to investigate PTEN restoration, PI3K/Akt signaling, mRNA delivery, and localized melanoma immunotherapy.

• U-73122 for PLC Signaling Workflows

  2026-08-15

  Build reproducible calcium-flux, chemotaxis, and breast-cancer invasion assays with U-73122, using concentration and timing controls that distinguish PLC dependence from general cytotoxicity. This practical guide connects phospholipase C inhibition to the QPRT–myosin light-chain findings while highlighting formulation, assay, and interpretation safeguards.

• Carbapenemase Gene Transmission in CREC

  2026-08-14

  Chen et al. characterize carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae collected across eight teaching hospitals in Guangdong, combining plasmid localization, antimicrobial susceptibility, conjugation, mobile-element analysis, and ERIC-PCR typing. The findings identify plasmid-associated blaNDM-1 as a major and highly transferable resistance determinant, while also showing genetically related isolates across departments and hospitals.

• Sulfamonomethoxine: Assay Design Across Biology

  2026-08-14

  Explore how Sulfamonomethoxine and SMM can be evaluated across antimicrobial, veterinary, and environmental workflows. This guide translates a canine susceptibility study into practical assay-design decisions while distinguishing product specifications from environmental evidence.

• GLI2, WNT, and Prostaglandins in Immunotherapy Resistance

  2026-08-13

  DeVito et al. identify GLI2 as a mechanistic link between mesenchymal transformation, tumor immune evasion, and resistance to anti-PD-1 therapy. Their study shows that GLI2 coordinates WNT ligand production and prostaglandin signaling to reshape myeloid and lymphoid immunity, providing a rationale for pathway-informed combination treatment strategies.

• LY2228820: Designing Better p38 MAPK Assays

  2026-08-13

  LY2228820 is a selective p38 MAP kinase inhibitor that can do more than suppress downstream phosphorylation. This guide shows how to design time-resolved, orthogonal assays that distinguish kinase blockade from altered dephosphorylation dynamics in inflammation and cancer research.

• Hypoxia and Immunometabolism in Tumors

  2026-08-12

  This 2025 review integrates tumor hypoxia, metabolic reprogramming, and immune-cell dysfunction into a single model of immunosuppressive tumor microenvironment evolution. Its practical value lies in identifying metabolic competition and hypoxia-responsive signaling as connected therapeutic and experimental targets, while highlighting the need for compartment-resolved and redox-aware measurements.

• Cl-Amidine (trifluoroacetate salt) Guide

  2026-08-12

  A scenario-based guide to using Cl-Amidine (trifluoroacetate salt), SKU C3829, in PAD4, NET, viability, proliferation, and cytotoxicity workflows. It connects formulation data with published CML findings and provides practical controls for reproducible interpretation.

• IEM 1460 for AMPA Receptor Research

  2026-08-11

  IEM 1460 is a selective AMPA receptor blocker for separating fast glutamatergic signaling from downstream excitotoxic injury. This practical guide covers receptor inhibition assays, electrophysiology, neuroprotection workflows, storage, controls, and troubleshooting while distinguishing IEM 1460 from the dual-target compound evaluated in recent seizure research.

• Epacadostat: Designing Better IDO1 Immune Assays

  2026-08-11

  Epacadostat and INCB024360 enable a layered strategy for studying IDO1-mediated immune regulation. This guide connects biochemical inhibition, whole-blood immunometabolism, cytokine analysis, and translational immuno-oncology decisions without confusing pathway engagement with therapeutic proof.

• U0126-EtOH: MEK1/2 Inhibitor Workflows

  2026-08-10

  U0126-EtOH provides a practical way to suppress MEK1/2–ERK1/2 signaling in neuronal, inflammatory, and differentiation assays. This guide connects pathway-selective experimental design with stock preparation, assay controls, troubleshooting, and interpretation of cross-model results.

• E-4031: From hERG Blockade to Translational Insight

  2026-08-09

  E-4031 is a benchmark hERG potassium channel blocker for connecting ion-channel mechanism with QT interval prolongation, torsades de pointes (TdP) induction, and proarrhythmic substrate modeling. This thought-leadership guide explains how translational researchers can use the compound in cardiac electrophysiology research, 3D cardiac models, and evidence-driven preclinical safety workflows while avoiding overinterpretation of hERG blockade alone.

• AS1842856: Reading Foxo1 Pathway Causality

  2026-08-08

  AS1842856 is a selective Foxo1 inhibitor for separating transcription-factor activity from protein abundance in metabolic assays. This guide connects hepatic glucose-production studies with the KDM4D–PI3K-Akt–Foxo1 findings in mesenchymal stem cells and provides a causality-focused experimental framework.

• EPI-001 Workflows for AR Signaling Research

  2026-08-07

  EPI-001 is an androgen receptor N-terminal domain inhibitor suited to experiments that need to probe ligand-dependent and ligand-independent AR activity, including AR variant biology. This workflow connects prostate cancer cell growth inhibition with a translational TNBC metastasis assay strategy while emphasizing formulation, controls, and interpretation.

8301 records 3/554 page Previous Next 12345 下5页 Last page